A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Citations
17 citations
17 citations
17 citations
Cites result from "A Next Generation Connectivity Map:..."
...In this work, we have showed the results between DeCoST and the Broad Institute CMAP, which is among the most well-known and comprehensive platforms for drug repurposing....
[...]
...Unfortunately, we could not compare between CMAP and DeCoST at this point....
[...]
...Therefore, we believe that DeCoST could provide complimentary advantages, in addition to CMAP....
[...]
...Second, due to several factors in experimental design, CMAP does not contains cell line for Breast Cancer ER- and Bladder Cancer....
[...]
...DeCoST focuses primarily on recommending drugs that have never been in disease-specific clinical trials; meanwhile, CMAP (https://clue. io/repurposing-app) primarily reports on drugs that has been under early phases of clinical trials....
[...]
17 citations
17 citations
Cites background or methods from "A Next Generation Connectivity Map:..."
...Differential expression values were calculated as moderated z-scores for each landmark gene and each unique perturbation (chemical and dose combination) perturbation, collapsed to a single value across replicates (Subramanian et al. 2017)....
[...]
...This platform was used in the creation of the Connectivity Map (CMap) (Subramanian et al. 2017), which now includes 1.3 million perturbation profiles of drugs and small molecules and has been instrumental in the discovery of small-molecule MoAs....
[...]
...Detailed cell culture, plating, treatment and lysis protocols are described in https://assets.clue.io/resources/sop-cell.pdf (Subramanian et al. 2017)....
[...]
...TAS>0:2 is the standard cutoff for sufficient bioactivity adopted by the CMap–L1000 workflow (Subramanian et al. 2017), while TAS>0:3 and TAS>0:4 represent more stringent thresholds we used to assess the effect of increasing bioactivity on downstream analysis, such as classification and gene set…...
[...]
...…each of our signatures and each of the perturbation signatures in the CMap, which comprises ∼ 1:3million profiles corresponding to 19,811 drugs and small molecules, and 5,075 molecular (gene-specific knockdown and overexpression) perturbations across 3 to 77 cell lines (Subramanian et al. 2017)....
[...]
References
34,830 citations
30,124 citations
10,968 citations
8,326 citations
6,319 citations